US20220347157A1 - Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane - Google Patents
Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane Download PDFInfo
- Publication number
- US20220347157A1 US20220347157A1 US17/691,911 US202217691911A US2022347157A1 US 20220347157 A1 US20220347157 A1 US 20220347157A1 US 202217691911 A US202217691911 A US 202217691911A US 2022347157 A1 US2022347157 A1 US 2022347157A1
- Authority
- US
- United States
- Prior art keywords
- composition
- canceled
- azabicyclo
- naphthalen
- hexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HKHCSWPSUSWGLI-CABCVRRESA-N (1r,5s)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane Chemical compound C1=CC=CC2=CC([C@@]34CNC[C@H]4C3)=CC=C21 HKHCSWPSUSWGLI-CABCVRRESA-N 0.000 title claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 38
- 238000013268 sustained release Methods 0.000 title claims abstract description 26
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 140
- 150000003839 salts Chemical group 0.000 claims abstract description 57
- -1 e.g Chemical compound 0.000 claims description 43
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 35
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 35
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 33
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 27
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 25
- 235000019359 magnesium stearate Nutrition 0.000 claims description 17
- ACVMJAJGCQUPKX-LIOBNPLQSA-N (1r,5s)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane;hydrochloride Chemical group Cl.C1=CC=CC2=CC([C@@]34CNC[C@H]4C3)=CC=C21 ACVMJAJGCQUPKX-LIOBNPLQSA-N 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 7
- 229920000609 methyl cellulose Polymers 0.000 claims description 7
- 239000001923 methylcellulose Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 229940033134 talc Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
- 229960001021 lactose monohydrate Drugs 0.000 description 10
- 229960003943 hypromellose Drugs 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002825 dopamine reuptake Effects 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000000966 norepinephrine reuptake Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000037058 blood plasma level Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000005153 frontal cortex Anatomy 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- ZFPZEYHRWGMJCV-LNLFQRSKSA-N methyl (3as,4r,7as)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2h-indole-1-carboxylate Chemical compound C([C@@]1(O)CCC[C@H]2[C@@H]1CCN2C(=O)OC)#CC1=CC=CC(C)=C1 ZFPZEYHRWGMJCV-LNLFQRSKSA-N 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 210000001009 nucleus accumben Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000002442 prefrontal cortex Anatomy 0.000 description 3
- 210000001103 thalamus Anatomy 0.000 description 3
- 210000004515 ventral tegmental area Anatomy 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- UNFQKKSADLVQJE-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4h-imidazol-2-yl)urea;hydrate Chemical compound O.CN1CC(=O)N=C1NC(=O)NC1=CC=CC(Cl)=C1 UNFQKKSADLVQJE-UHFFFAOYSA-N 0.000 description 2
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 2
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000003691 GABA modulator Substances 0.000 description 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 229960004047 acamprosate Drugs 0.000 description 2
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- UPZWINBEAHDTLA-UHFFFAOYSA-N basimglurant Chemical compound CC=1N(C=2C=CC(F)=CC=2)C(C)=NC=1C#CC1=CC=NC(Cl)=C1 UPZWINBEAHDTLA-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LZXMUJCJAWVHPZ-UHFFFAOYSA-N dipraglurant Chemical compound C=1N2C=C(F)C=CC2=NC=1CCC#CC1=CC=CC=N1 LZXMUJCJAWVHPZ-UHFFFAOYSA-N 0.000 description 2
- 229950008093 dipraglurant Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229950002489 fenobam Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229920003130 hypromellose 2208 Polymers 0.000 description 2
- 229940031707 hypromellose 2208 Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000003174 triple reuptake inhibitor Substances 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- HKHCSWPSUSWGLI-LSDHHAIUSA-N (1s,5r)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane Chemical compound C1=CC=CC2=CC([C@]34CNC[C@@H]4C3)=CC=C21 HKHCSWPSUSWGLI-LSDHHAIUSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- HKHCSWPSUSWGLI-UHFFFAOYSA-N 1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane Chemical compound C1=CC=CC2=CC(C34CNCC4C3)=CC=C21 HKHCSWPSUSWGLI-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- ANDGGVOPIJEHOF-UHFFFAOYSA-N CX-516 Chemical compound C=1C=C2N=CC=NC2=CC=1C(=O)N1CCCCC1 ANDGGVOPIJEHOF-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 229940047812 adderall Drugs 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229950006826 arbaclofen Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940127592 mGluR2/3 antagonist Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
- (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane is an unbalanced triple reuptake inhibitor with the most potency towards norepinephrine reuptake (NE), one-sixth as much towards dopamine reuptake (DA), and one-fourteenth as much towards serotonin reuptake (5-HT).
- There remains a need for novel pharmaceutical compositions comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
- Provided is a pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
- Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of this disclosure, are intended for purposes of illustration only and are not intended to limit the scope of this disclosure.
- The following description of the preferred embodiment(s) is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.
- As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In addition, all references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
- (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, also known as (+)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0]hexane, is shown as Formula I below.
- “(1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo [3.1.0]hexane” and “(+)-1-(naphthalen-2-yl)-3-azabicyclo[3 .1.0]hexane” are used interchangeably herein.
- (1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo [3.1.0]hexane is an unbalanced triple reuptake inhibitor with the most potency towards norepinephrine reuptake (NE), one-sixth as much towards dopamine reuptake (DA), and one-fourteenth as much towards serotonin reuptake (5-HT).
- (1R,5S)-1-(naphtha len-2-yl)-3 -azabicyclo [3.1.0] hexane may be synthesized as described in U.S. Pat. No. 8,461,196 or International Publication No. WO 2013/019271, both of which are incorporated herein by reference in their entirety.
- As used herein, “substantially free of the corresponding (—) enantiomer” means more of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane than the corresponding (—) enantiomer, i.e., (1S ,5R)-1-(naphthalen-2-yl)-3 -azabicyclo[3.1.0] hexane. In some embodiments, “substantially free of the corresponding (—) enantiomer” means containing no more than 20% w/w (weight/weight) of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 10% w/w of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 5% w/w of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 2% w/w of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 1% w/w of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form.
- As used herein, “(1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0]hexane” embraces the compound in any form, for example, free or pharmaceutically acceptable salt form, e.g., as a pharmaceutically acceptable acid addition salt. Pharmaceutically acceptable salts are known in the art and include salts that are physiologically acceptable at the dosage amount and form to be administered, for example, hydrochloride salts.
- As used herein, “(1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo[3.1.0]hexane” is also to be understood as embracing the compound in crystalline and amorphous form including, for example, polymorphs, solvates (including hydrates), unsolvated polymorphs (including anhydrates), conformational polymorphs, and amorphous forms of the compounds, as well as mixtures thereof. “Crystalline form” and “polymorph” may be used interchangeably herein, and are meant to include all crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, including, for example, polymorphs, solvates (including hydrates), unsolvated polymorphs (including anhydrates), and conformational polymorphs, as well as mixtures thereof, unless a particular crystalline form is referred to.
- Crystalline and amorphous forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane may be used in any combination or in forms that are substantially free of one or more of the other crystalline forms or free of the amorphous form.
- (1R, 5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane may in some cases also exist in prodrug form. Prodrugs are considered to be any covalently bonded carriers that release the active parent drug in vivo.
- As used herein, “concurrently” means the compounds are administered simultaneously or within the same composition. In some embodiments, the compounds are administered simultaneously. In some embodiments, the compounds are administered within the same composition.
- The nominal viscosity of polymers, e.g., hydroxypropyl methylcellulose may be measured, for example, at a 2% concentration in water at 20° C. according to the U.S. Pharmacopeia and by other techniques known to those skilled in the art.
- Particle size measurements may be made, for example, by laser diffraction and by other techniques known to those skilled in the art.
- In some embodiments, the pharmaceutical compositions disclosed herein comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, may be administered by any suitable route, including orally, parenterally, transdermally, or by inhalation, including by sustained release, although various other known delivery routes, devices and methods can likewise be employed. In some embodiments, provided is a sustained release pharmaceutical composition, e.g., an oral sustained release pharmaceutical composition, comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0] hexane, in free or pharmaceutically acceptable salt form, which provides therapeutically effective levels of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane over a sustained delivery period of approximately 6 hours or longer, e.g., 8 hours or longer, e.g., 12 hours or longer, e.g., 18 hours or longer, e.g., 24 hours or longer.
- In some embodiments, (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that from about 0% to 20% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 0 to 2 hours, from 20% to 50% of the active compound is released and delivered within about 2 to 12 hours, from 50% to 85% of the active compound is released and delivered within about 3 to 20 hours, and greater than 75% of the active compound is released and delivered within about 5 to 18 hours.
- In some embodiments, (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0] hexane, in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that at least 20% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 4 or less hours after administration, e.g., at least about 30%, e.g., at least about 40%, e.g., about 20-80%, e.g., about 30-70%, e.g., about 40-60% is released and delivered within 4 hours or less after administration.
- In some embodiments, (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0] hexane, in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that at least 50% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 8 hours or less after administration, e.g., at least about 60%, e.g., at least about 70%, e.g., at least about 80%, e.g., about 50-90%, e.g., about 60-90%, e.g., about 60-80% is released and delivered within 8 hours or less after administration.
- In some embodiments, at least 20% of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, e.g., at least about 30%, e.g., at least about 40%, e.g., about 20-80%, e.g., about 30-70%, e.g., about 30-60%, e.g., about 40-60%, e.g., about 50-60%, e.g., about 50%, e.g., about 60%, is released and dissolved within 4 hours or less (e.g., within about 2-4 hours, e.g., about within 3-4 hours, e.g., about 4 hours) from a pharmaceutical composition as disclosed herein as measured in 900 mL water using USP Apparatus 2 paddle, at 50 rpm and at 37° C.±0.5. In addition, in some embodiments, at least 50% of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, e.g., at least about 60%, e.g., at least about 70%, e.g., at least about 80%, e.g., about 50-90%, e.g., about 60-90%, e.g., about 60-80% is released and dissolved within 8 hours or less (e.g., within about 6-8 hours, e.g., within about 7-8 hours, e.g., about 8 hours) from a pharmaceutical composition as disclosed herein as measured in 900 mL water using USP Apparatus 2 paddle, at 50 rpm and 37° C.±0.5.
- In some embodiments, the Cmax of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is less than about 80%, e.g., less than about 75%, e.g., less than about 60%, e.g., less than about 50%, e.g., less than about 40%, e.g., less than about 30% of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition. In some embodiments, the Cmax of (1R,5S)-1-(naphthalen-2-y1)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is about 20-80%, e.g., is about 30-80%, e.g., is about 20-70% e.g., is about 30-70%, e.g., is about 30-60%, e.g., is about 30-50%, e.g., is about 30-40%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
- (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphth alen-2-yl)-3- azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is less than about 50%, e.g., less than about 40%, e.g., less than about 30%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition. In some embodiments, the Cmax of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0] hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is about 20-50%, e.g., is about 30-50%, e.g., is about 30-40%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo [3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
- In some embodiments, the pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, e.g., a sustained release pharmaceutical composition, comprises a lubricant, e.g., magnesium stearate, a carrier, e.g., lactose monohydrate, or a combination thereof.
- Provided is a pharmaceutical composition (Composition 1), e.g., a sustained release pharmaceutical composition, comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
- Further provided is Composition 1 as follows:
- 1.1 Composition 1 wherein the composition is sustained release.
1.2 Composition 1 or 1.1 wherein the pharmaceutical composition is substantially free of the corresponding (—) enantiomer.
1.3 Composition 1, 1.1, or 1.2 wherein the composition comprises less than or equal to 20% w/w of the corresponding (—) enantiomer.
1.4 Any of Compositions 1 or 1.1-1.3 wherein the composition comprises less than or equal to 10% w/w of the corresponding (—) enantiomer.
1.5 Any of Compositions 1 or 1.1-1.4 wherein the composition comprises less than or equal to 5% w/w of the corresponding (—) enantiomer.
1.6 Any of Compositions 1 or 1.1-1.5 wherein the composition comprises less than or equal to 2% w/w of the corresponding (—) enantiomer.
1.7 Any of Composition 1 or 1.1-1.6 wherein the composition comprises less than or equal to 1% w/w of the corresponding (—) enantiomer.
1.8 Any of Compositions 1 or 1.1-1.7 wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane is in pharmaceutically acceptable salt form.
1.9 Composition 1.8 wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is an acid addition salt.
1.10 Composition 1.9 wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride.
1.11 Any of Compositions 1 or 1.1-1.10 comprising 1 mg to 1800 mg, e.g., 10 mg to 1800 mg, e.g., 25 mg to 1800 mg, e.g., 10 mg to 1600 mg, e.g., 10 mg to 1200 mg, e.g., 50 mg to 1200 mg, e.g., 50 mg to 1000 mg, e.g., 75 mg to 1000 mg, e.g., 75 mg to 800 mg, e.g., 75 mg to 500 mg, e.g., 100 mg to 750 mg, e.g., 100 mg to 500 mg, e.g., 100 mg to 400 mg, e.g., 100 mg to 300 mg, e.g., 100 mg to 200 mg, of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.12 Any of Compositions 1 or 1.1-1.11 comprising 75 mg to 1000 mg, e.g., 100 mg to 600 mg, e.g., 100 mg to 400 mg, e.g., 100 mg to 200 mg, of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.13 Any of Compositions 1 or 1.1-1.11 comprising 50 mg to 600 mg, e.g., 100 mg to 600 mg, e.g., 100 mg to 400 mg, e.g., 100 mg to 200 mg, of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.14 Any of Compositions 1 or 1.1-1.11 comprising 5 mg to 500 mg, e.g., 5 mg to 10 mg, e.g, 10 mg to 25 mg, e.g., 30 mg to 50 mg, e.g., 10 mg to 300 mg, e.g., 25 mg to 300 mg, e.g., 50 mg to 100 mg, e.g., 100 mg to 250 mg, e.g., 250 mg to 500 mg, of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.15 Any of Compositions 1 or 1.1-1.10 for administration of 0.5 mg/kg to 20 mg/kg per day, e.g., 1 mg/kg to 15 mg/kg per day, e.g., 1 mg/kg to 10 mg/kg per day, e.g., 2 mg/kg to 20 mg/kg per day, e.g., 2 mg/kg to 10 mg/kg per day, e.g., 3 mg/kg to 15 mg/kg per day, of (1R,5 S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.16 Any of Compositions 1 or 1.1-1.15 comprising less than 50% w/w of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, e.g., less than about 40% w/w, e.g., less than about 30% w/w, less than about 20% w/w, e.g., about 1-40% w/w, e.g., about 5-40% w/w, e.g., about 10-30% w/w, e.g., about 15-25% w/w, e.g., about 15-20% w/w, e.g., about 17% w/w, e.g., about 25% w/w. 1.17 Any of Compositions 1 or 1.1-1.16 further comprising hydroxypropyl methylcellulose (e.g., hypromellose HPMC K4M).
1.18 Composition 1.17 wherein the composition comprises at least 10% w/w of the hydroxypropyl methylcellulose, e.g., about 10-50% w/w, e.g., about 10-40% w/w, e.g., about 20-50% w/w, e.g., about 20-40% w/w, e.g., about 30-40% w/w, e.g., about 37% w/w.
1.19 Composition 1.17 or 1.18 wherein the degree of methoxy substitution of the hydroxypropyl methylcellulose is 19-24%.
1.20 Any of Compositions 1.17-1.19 wherein the degree of hydroxypropoxy substitution of the hydroxypropyl methylcellulose is 4-12%.
1.21 Any of Compositions 1.17-1.20 wherein the hydroxypropyl methylcellulose is hypromellose 2208.
1.22 Any of Compositions 1.17-1.21 wherein the hydroxypropyl methylcellulose has a nominal viscosity of 4,000 mPA·s.
1.23 Any of Compositions 1.17-1.21 wherein the hydroxypropyl methylcellulose has a viscosity of 2,000-6,000 mPA·s, e.g., about 2,600 to 5,000 mPA·s, e.g., about 2,663 to 4,970 mPA·s.
1.24 Any of Compositions 1 or 1.1-1.23 wherein the composition further comprises lactose (e.g., alpha-lactose monohydrate).
1.25 Composition 1.24 wherein the composition comprises at least 10% w/w of the alpha-lactose monohydrate, e.g., about 10-80% w/w, e.g., about 20-70% w/w, e.g., about 20-60% w/w, e.g., about 20-50% w/w, e.g., about 20-40% w/w, e.g., about 20-30% w/w, e.g., about 30-70% w/w, e.g., about 30-60% w/w, e.g., about 30-50% w/w, e.g., about 30%-40% w/w, e.g., about 37% w/w.
1.26 Composition 1.24 or 1.25 wherein the composition comprises milled alpha-lactose monohydrate.
1.27 Any of Compositions 1 or 1.1-1.26 wherein the composition comprises a co-processed mixture of hydroxpropyl methylcellulose and alpha-lactose monohydrate (e.g., Retalae).
1.28 Composition 1.27 wherein the mixture comprises equal parts of the hydroxpropyl methylcellulose and alpha-lactose monohydrate.
1.29 Composition 1.27 or 1.28 wherein the mixture comprises particles of hydroxpropyl methylcellulose and alpha-lactose monohydrate with d50 (median diameter) in the range of 100 to 200 gym, e.g., about 125
1.30 Any of Compositions 1.27-1.29 wherein the mixture comprises particles of hydroxpropyl methylcellulose and alpha-lactose monohydrate wherein the particle size distribution is as follows: -
- <63 μm≤25%
- <100 μm: 35%
- <250 μm≥80%.
1.31 Any of Compositions 1.27-1.30 wherein the composition comprises at least 20% w/w of the mixture, e.g., about at least 30% w/w, e.g., at least about 40% w/w, e.g., at least about 50% w/w, e.g., at least about 60% w/w, e.g., at least about 70% w/w, e.g, at least about 80% w/w, e.g., about 20-90% w/w, e.g., about 30-80% w/w, e.g., about 40-80% w/w, e.g., about 50-80% w/w, e.g., about 60-80% w/w, e.g., about 70-80% w/w, e.g., about 75% w/w.
1.32 Any of Compositions 1 or 1.1-1.31 wherein the composition further comprises a lubricant, e.g., magnesium stearate.
1.33 Composition 1.32 wherein the lubricant is one or more of glyceryl behenate, magnesium stearate, talc, and sodium stearyl fumarate, e.g, magnesium stearate.
1.34 Composition 1.32 or 1.33 wherein the composition comprises less than 10% w/w of the lubricant, e.g., less than about 5% w/w, less than about 3% w/w, less than about 1% w/w, e.g., about 0.1 to 1% w/w, e.g., about 0.1 to 0.8% w/w, e.g., about 0.5% w/w.
1.35 Any of Compositions 1.32-1.34 wherein the composition comprises less than 10% w/w of magnesium stearate, e.g., less than about 5% w/w, less than about 3% w/w, less than about 1%, e.g., about 0.1 to 1% w/w, e.g., about 0.1 to 0.8% w/w, e.g., about 0.5% w/w.
1.36 Any of Compositions 1 or 1.1-1.35 wherein the composition further comprises one or more of a diluent, disintegrant, binder, and modified release agent.
1.37 Composition 1.36 wherein the diluent is one or more of mannitol (e.g., Pearlitol 300 DC), micro-crystalline cellulose (e.g., Avicel pH 102), and pre-gelatinized starch (e.g., Starch 1500).
1.38 Composition 1.36 wherein the disintegrant is one or both of crospovidone (e.g.,
- Polyplasdone XL-10) and sodium starch glycolate (e.g., Explotab).
- 1.39 Composition 1.36 wherein the binder is polyvinylpyrrolidone (e.g., Povidone K29/32).
1.40 Composition 1.36 wherein the modified release agent is one or more of hydroxypropyl cellulose (e.g., Klucel EXF, Klucel MXF and/or Klucel HXF) and hydroxypropyl methylcellulose (e.g., Methocel K100M, Methocel K4M PREM, Methocel K15M PREM CR).
1.41 Composition 1.36 or 1.40 wherein the composition comprises at least 5% w/w of the modified release agent, e.g., about 5-60% w/w, e.g., about 10-50% w/w, e.g., about 10-40% w/w.
1.42 Composition 1.40 or 1.41 wherein the modified release agent is hydroxypropyl methylcellulose.
1.43 Composition 1.42 wherein the degree of methoxy substitution of the hydroxypropyl methylcellulose is 19-24%.
1.44 Composition 1.42 or 1.43 wherein the degree of hydroxypropoxy substitution of the hydroxypropyl methylcellulose is 4-12%.
1.45 Any of Compositions 1.42-1.44 wherein the hydroxypropyl methylcellulose is hypromellose 2208.
1.46 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 75,000-140,000 mPA·s.
1.47 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 2,000-6,000 mPAs, e.g., about 2,600 to 5,000 mPAs, e.g., about 2,663 to 4,970 mPA·s.
1.48 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 12,000-26,000 mPAs, e.g., about 13,000 to 25,000 mPA·s, e.g., about 13,275 to 24,780 mPA·s.
1.49 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 100,000 cps.
1.50 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 3,600 cps.
1.51 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 18,000 cps.
1.52 Composition 1.36, 1.40, or 1.41 wherein the modified release agent is hydroxypropyl cellulose (e.g., Klucel EXF, Klucel MXF and/or Klucel HXF).
1.53 Any of Compositions 1 or 1.1-1.52 for administration once, twice, three, or four times daily.
1.54 Any of Compositions 1 or 1.1-1.53 further comprising another drug.
1.55 Any of Compositions 1 or 1.1-1.54 wherein the composition further comprises an mG1uR1 antagonist, an mGluR2/3 antagonist, an mGluR5 antagonist, an AMPA receptor positive modulator, an NMDA receptor antagonist, a tetracycline antibiotic, an α2-adrenergic agonist, an antipsychotic, an anti-depressant (e.g., a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), or a tricyclic anti-depressant), a benzodiazepine, an anti-convulsant, a mood stabilizer, a gamma-aminobutyric acid (GABA) agonist e.g., a GABA-B agonist, a GABA modulator, a stimulant, a β-blocker, a hormone, or a combination thereof.
1.56 Any of Compositions 1 or 1.1-1.55 wherein the composition further comprises fenobam, mavoglurant (AFQ056), dipraglurant, R04917523, STX107, 2-methyl-6-phenylethynyl pyridine (MPEP), CX516, memantine, acamprosate, minocycline, clonidine, guanfacine, aripiprazole, risperidone, citalopram, escitalopram, fluoxetine, sertraline, fluovoxamine, paroxetine, trazodone, bupropion, imipramine, amitriptyline, venlafaxine, nefazodone, duloxetine, venlafaxine, carbamazepine, lamotrigine, valproic acid, sodium valproatc, lithium, quctiapinc, folic acid, L-acctylcarnitinc, mclatonin, arbaclofcn, doncpczil hydrochloride, alpha-tocopherol, methylphenidate, amphetamine mixed salts (e.g., Adderall), dextroamphetamine, risperidone, olanzapine, ziprasidone, buspirone, filuzole, metadoxine, primidone, topiramate, estradiol, cyclic medroxyprogesterone, or a combination thereof.
1.57 Any of Compositions 1 or 1.1-1.56 further comprising an mGluR5 antagonist.
1.58 Composition 1.57 further comprising fenobam, mavoglurant (AFQ056), dipraglurant, RO4917523, STX107, 2-methyl-6-phenylethynyl pyridine (MPEP), or a combination thereof
1.59 Composition 1.58 further comprising RO4917523, mavoglurant (AFQ056), or a combination thereof.
1.60 Any of Compositions 1 or 1.1-1.59 further comprising a GABA-B agonist.
1.61 Composition 1.60 comprising arbaclofen.
1.62 Any of Compositions 1 or 1.1-1.61 further comprising a GABA modulator.
1.63 Composition 1.62 further comprising acamprosate.
1.64 Any of Compositions 1 or 1.1-1.63 further comprising minocycline.
1.65 Any of Compositions 1 or 1.1-1.64 wherein the Cmax of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of the composition is less than about 80%, e.g., less than about 75%, e.g., less than about 60%, e.g., less than about 50%, e.g., less than about 40%, e.g., less than about 30%, e.g., is about 20-80%, e.g., is about 30-80%, e.g., is about 20-70% e.g., is about 30-70%, e.g., is about 30-60%, e.g., is about 30-50%, e.g., is about 30-40%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
1.66 Any of Compositions 1 or 1.1-1.65 wherein the Cmax of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, is less than about 50%, e.g., less than about 40%, e.g., less than about 30%, e.g., about 20-50%, e.g., about 30-50%, e.g., about 30-40%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
1.67 Composition 1 wherein the composition comprises 25% w/w (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, 74.5% w/w of an equal parts mixture of hydroxypropyl methylcellulose and alpha-lactose monohydrate, and 0.5% w/w magnesium stearate.
1.68 Any of Compositions 1 or 1.1-1.67 for use in indications as described in U.S. Pat. No. 8,461,196, International Publication No. WO 2013/019271, and International Patent Application No. PCT/US14/69401, the contents of each of which are hereby incorporated by reference. - Sustained release pharmaceutical compositions comprising (1R,5S)-1 -(naphthalen-2-yl)-3-azabicyclo [3.1.0]hexanehydrochloride may be made utilizing a direct blend process, with screening of the excipients and (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride through a Quadro 197S Co-Mil, and blending in a V-shell blender prior to compression on a rotary tablet press.
- Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
-
Concentration Tablet Unit Ingredient (% W/W) Weight (mg) (1R,5S)-1-(naphthalen-2- 25% 100 yl)-3-azabicyclo[3.1.0]hexane hydrochloride Lactose Monohydrate, NF 74.5% 298 Hypromellose, NF (as 50/50 premix - RetaLac ®) Magnesium Stearate, NF 0.5% 2 (Hyqual ® Vegetable source) Total 100% 400 - HPLC conditions for dissolution and dissolution conditions for Examples 3-9 are set forth in Tables 1 and 2.
-
TABLE 1 HPLC Conditions Dissolution Item Setting Column Waters XBridge C18 3.0 × 150 mm 3.5 μm Mobile Phase MPA: 6 mM Ammonium Formate; 95% Water, 5% CAN MPB: 5 mM Ammonium Formate; 5% Water, 95% ACN Flow Rate See Gradient Detection 226 nm Column Temp. 40° C. Run Time 42 minutes Injection Volume 20 μL Flow Rate Gradient Time % MPA % MPB (mL/min) 0 95 5 0.8 30 50 50 0.8 30.1 5 95 0.8 35 5 95 1.2 35.1 95 5 0.8 42 95 5 0.8 -
TABLE 2 Dissolution Testing Conditions Item Setting/Condition Media Water Volume 900 mL Speed 50 rpm Apparatus USP, App. 2, Paddle Temp. 37° C. ± 0.5 - Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
- Manufacture by a direct blend process. Compress on Dynamic Exim rotary tablet press using concave ⅜″ tooling. Compress at a target weight of 300 mg (±15 mg) and target hardness of approximately 8kp±2 kp.
-
Concentration Tablet Unit Ingredient (% W/W) Weight (mg) (1R,5S)-1-(naphthalen-2- 16.7% 50 yl)-3-azabicyclo[3.1.0]hexane hydrochloride Lactose Monohydrate, NF 82.8% 248.5 Hypromellose, NF (as 50/50 premix - RetaLac ®) Magnesium Stearate, NF 0.5% 1.5 Total 100% 300 -
TABLE 3 Dissolution Data: Numerical Data 12-hour dissolution profile Vessel 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 1 23 35 52 65 74 64 2 22 33 51 64 73 84 3 21 34 50 64 73 84 Ave 22 34 51 64 73 84 % RSD 3.0 2.3 1.8 1.0 0.6 0.2 - Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
- Manufacture by a direct blend process. Compress on Dynamic Exim rotary tablet press using concave ⅜″ tooling. Compress at a target weight of 300 mg (±15 mg) and target hardness of approximately 8kp±2 kp.
-
Concentration Tablet Unit Ingredient (% W/W) Weight (mg) (1R,5S)-1-(naphthalen-2- 16.7% 50 yl)-3-azabicyclo[3.1.0]hexane hydrochloride Lactose Monohydrate, NF 42.8% 128.4 Hypromellose, NF (as 50/50 premix - RetaLac ®) Lactose Monohydrate, 315 SD 40.0% 120.0 Magnesium Stearate, NF 0.5% 1.5 Total 100% 300 -
TABLE 4 Vessel 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr 1 32 48 66 78 85 94 99 2 30 45 66 79 90 84 96 3 33 48 70 79 89 84 89 Ave 32 47 67 78 88 87 95 % RSD 3.6 4.6 3.9 0.8 2.8 6.8 5.4 - Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
- Manufacture by a direct blend process. Compress on Dynamic Exim rotary tablet press using concave ⅜″ tooling. Compress at a target weight of 300 mg (±15 mg) and target hardness of approximately 8 kp±2 kp.
-
Concentration Tablet Unit Ingredient (% W/W) Weight (mg) (1R,5S)-1-(naphthalen-2- 16.7% 50 yl)-3-azabicyclo[3.1.0]hexane hydrochloride Lactose Monohydrate, NF 52.8% 158.5 Hypromellose, NF (as 50/50 premix - RetaLac ®) Klucel HXF HPC 30.0% 90.0 Magnesium Stearate, NF 0.5% 1.5 Total 100% 300 -
TABLE 5 Vessel 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr 1 29 46 67 75 92 101 105 2 29 43 65 74 91 94 106 3 30 43 65 75 87 101 105 Ave 30 44 66 75 90 99 105 % RSD 2.0 3.5 1.6 0.7 3.0 4.3 0.6 - Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
-
Concentration Tablet Unit Ingredient (% W/W) Weight (mg) (1R,5S)-1-(naphthalen-2- 16.7% 50 yl)-3-azabicyclo[3.1.0]hexane hydrochloride Lactose Monohydrate, 315 SD 41.4% 124.25 HPMC K4M 41.4% 124.25 Magnesium Stearate, NF 0.5% 1.5 Total 100% 300 -
TABLE 6 Vessel 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr 1 24 37 55 68 78 88 92 2 21 33 51 63 76 92 95 3 22 34 52 62 77 93 100 4 24 38 56 72 86 100 100 5 22 34 51 63 71 84 88 6 23 36 55 66 75 98 104 Ave 23 35 53 66 77 92 96 % RSD 5.2 4.9 4.2 5.7 6.4 6.4 6.1 - Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
-
Concentration Tablet Unit Ingredient (% W/W) Weight (mg) (1R,5S)-1-(naphthalen-2- 33.3% 100 yl)-3-azabicyclo[3.1.0]hexane hydrochloride Lactose Monohydrate, NF 66.2% 198.5 Hypromellose, NF (as 50/50 premix - RetaLac ®) Magnesium Stearate, NF 0.5% 1.5 (Hyqual ® Vegetable source) Total 100% 300 -
TABLE 7 Vessel 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr 1 21 33 53 69 84 — — 2 21 34 54 68 81 — — 3 23 35 57 69 80 — — 4 22 31 54 68 83 — — 5 22 35 56 71 83 — — 6 23 36 57 69 87 — — Ave 22 34 55 69 83 — — % RSD 5.0 4.8 3.6 1.5 3.0 — — NOTE: 12 and 24 hour pulls not performed - Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
-
Concentration Tablet Unit Ingredient (% W/W) Weight (mg) (1R,5S)-1-(naphthalen-2- 25.0% 100 yl)-3-azabicyclo[3.1.0]hexane hydrochloride Lactose Monohydrate, NF 74.5% 298.0 Hypromellose, NF (as 50/50 premix - RetaLac ®) Magnesium Stearate, NF 0.5% 2.0 (Hyqual ® Vegetable source) Total 100% 400 -
TABLE 8 Vessel 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr 1 20 20 47 60 73 — — 2 22 34 53 68 79 — — 3 22 33 47 68 79 — — 4 20 30 47 64 74 — — 5 19 30 43 59 69 — — 6 21 31 49 64 76 — — Ave 21 31 48 64 75 — — % RSD 5.5 6.6 7.3 5.7 5.0 — — NOTE: 12 and 24 hour pulls not performed - Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
-
Concentration Tablet Unit Ingredient (% W/W) Weight (mg) (1R,5S)-1-(naphthalen-2- 25.0% 100 yl)-3-azabicyclo[3.1.0]hexane hydrochloride Lactose Monohydrate, NF 74.5% 298.0 Hypromellose, NF (as 50/50 premix - RetaLac ®) Magnesium Stearate, NF 0.5% 2.0 (Hyqual ® Vegetable source) Total 100% 400 - Batch has an approximate 50% dissolution release at 4 hours and approximate 80% release at 8 hours.
Claims (46)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/691,911 US20220347157A1 (en) | 2013-12-09 | 2022-03-10 | Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361913886P | 2013-12-09 | 2013-12-09 | |
PCT/US2014/069416 WO2015102826A1 (en) | 2013-12-09 | 2014-12-09 | Novel compositions |
US201615102949A | 2016-06-09 | 2016-06-09 | |
US202117443763A | 2021-07-27 | 2021-07-27 | |
US17/691,911 US20220347157A1 (en) | 2013-12-09 | 2022-03-10 | Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US202117443763A Continuation | 2013-12-09 | 2021-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220347157A1 true US20220347157A1 (en) | 2022-11-03 |
Family
ID=53371779
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/102,949 Abandoned US20160303077A1 (en) | 2013-12-09 | 2014-12-09 | Novel compositions |
US15/102,871 Active US9839627B2 (en) | 2013-12-09 | 2014-12-09 | Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder |
US17/691,911 Pending US20220347157A1 (en) | 2013-12-09 | 2022-03-10 | Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/102,949 Abandoned US20160303077A1 (en) | 2013-12-09 | 2014-12-09 | Novel compositions |
US15/102,871 Active US9839627B2 (en) | 2013-12-09 | 2014-12-09 | Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder |
Country Status (8)
Country | Link |
---|---|
US (3) | US20160303077A1 (en) |
EP (1) | EP3080080A4 (en) |
JP (1) | JP2017502948A (en) |
KR (1) | KR20160101012A (en) |
CN (1) | CN106029637A (en) |
AU (1) | AU2014374259A1 (en) |
CA (1) | CA2936108A1 (en) |
WO (2) | WO2015089111A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1915146A4 (en) | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
KR20160101012A (en) | 2013-12-09 | 2016-08-24 | 뉴로반스, 인크. | Novel compositions |
CA2989431C (en) | 2015-06-17 | 2023-08-29 | Franklin Bymaster | Crystalline compounds |
WO2018119291A1 (en) * | 2016-12-21 | 2018-06-28 | Otsuka America Pharmaceutical, Inc. | Synthetic methods |
KR20210005663A (en) | 2018-04-26 | 2021-01-14 | 가부시키가이샤 에이피아이 코포레이션 | Method for producing an aromatic nitrile compound |
CN113365977A (en) | 2019-10-29 | 2021-09-07 | 株式会社Api | High-purity 2-naphthylacetonitrile and production method thereof |
WO2022181625A1 (en) | 2021-02-23 | 2022-09-01 | Otsuka Pharmaceutical Co., Ltd. | Centanafadine pharmaceutical formulations, and methods of making and using same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9708261B2 (en) * | 2015-06-17 | 2017-07-18 | Neurovance, Inc. | Crystalline compounds |
US9839627B2 (en) * | 2013-12-09 | 2017-12-12 | Neurovance, Inc. | Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder |
US20210267940A1 (en) * | 2011-07-30 | 2021-09-02 | Anthony Alexander McKINNEY | Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223875A1 (en) | 2005-03-08 | 2006-10-05 | Phil Skolnick | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes |
US20070082939A1 (en) | 2005-07-26 | 2007-04-12 | Lippa Arnold S | Methods and compositions for the treatment of neuropathies and related disorders |
EP1915146A4 (en) | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
US20080058535A1 (en) * | 2006-07-25 | 2008-03-06 | Zhengming Chen | Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes |
US20110034565A1 (en) * | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
US20120258994A1 (en) * | 2010-12-03 | 2012-10-11 | Mckinney Anthony Alexander | Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters |
AU2012223720A1 (en) * | 2011-03-03 | 2013-09-26 | Vanderbilt University | 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same |
DK2819516T3 (en) * | 2011-07-30 | 2020-03-16 | Otsuka America Pharmaceutical Inc | USE OF (1R, 5S) - (+) - 1- (NAPHTHALEN-2-YL) -3-AZABICYCLO {3.1.0} HEXAN IN THE TREATMENT OF DISEASES CONNECTED WITH MONOAMINE NEUROTRANSMITTERS |
US20140228421A1 (en) | 2011-09-07 | 2014-08-14 | Anthony McKinney | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters |
-
2014
- 2014-12-09 KR KR1020167018428A patent/KR20160101012A/en not_active Application Discontinuation
- 2014-12-09 WO PCT/US2014/069401 patent/WO2015089111A1/en active Application Filing
- 2014-12-09 AU AU2014374259A patent/AU2014374259A1/en not_active Abandoned
- 2014-12-09 US US15/102,949 patent/US20160303077A1/en not_active Abandoned
- 2014-12-09 CA CA2936108A patent/CA2936108A1/en not_active Abandoned
- 2014-12-09 CN CN201480074992.0A patent/CN106029637A/en active Pending
- 2014-12-09 US US15/102,871 patent/US9839627B2/en active Active
- 2014-12-09 EP EP14876251.1A patent/EP3080080A4/en not_active Withdrawn
- 2014-12-09 JP JP2016539110A patent/JP2017502948A/en not_active Withdrawn
- 2014-12-09 WO PCT/US2014/069416 patent/WO2015102826A1/en active Application Filing
-
2022
- 2022-03-10 US US17/691,911 patent/US20220347157A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210267940A1 (en) * | 2011-07-30 | 2021-09-02 | Anthony Alexander McKINNEY | Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters |
US9839627B2 (en) * | 2013-12-09 | 2017-12-12 | Neurovance, Inc. | Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder |
US9708261B2 (en) * | 2015-06-17 | 2017-07-18 | Neurovance, Inc. | Crystalline compounds |
US10800740B2 (en) * | 2015-06-17 | 2020-10-13 | Otsuka America Pharmaceutical, Inc. | Crystalline compounds |
Also Published As
Publication number | Publication date |
---|---|
US9839627B2 (en) | 2017-12-12 |
CN106029637A (en) | 2016-10-12 |
KR20160101012A (en) | 2016-08-24 |
AU2014374259A1 (en) | 2016-07-21 |
US20160303076A1 (en) | 2016-10-20 |
EP3080080A1 (en) | 2016-10-19 |
CA2936108A1 (en) | 2015-07-09 |
WO2015102826A1 (en) | 2015-07-09 |
EP3080080A4 (en) | 2017-08-16 |
JP2017502948A (en) | 2017-01-26 |
WO2015089111A1 (en) | 2015-06-18 |
US20160303077A1 (en) | 2016-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220347157A1 (en) | Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane | |
US10786507B2 (en) | Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof | |
US20070265276A1 (en) | Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders | |
US20080008752A1 (en) | Pharmaceutical compositions of memantine | |
KR101307334B1 (en) | Sustained-release pharmaceutical composition comprising pramipexole or pharmaceutically acceptable salt thereof having improved stability | |
US20110070319A1 (en) | Bifeprunox doses for treating schizophrenia | |
JP2011507973A (en) | Pharmaceutical composition of amlodipine and valsartan | |
US11273156B2 (en) | Stable cariprazine formulations for oral use | |
US20110274751A1 (en) | Trimetazidine formulation with different release profiles | |
US20140343076A1 (en) | Pharmaceutical compositions of lurasidone | |
US20120277257A1 (en) | Methods of Treating Diseases, Pharmaceutical Compositions, and Pharmaceutical Dosage Forms | |
US20180147148A1 (en) | Pharmaceutical composition of teriflunomide | |
KR20090013736A (en) | Sustained-release formulation comprising metformin acid salt | |
US20120329831A1 (en) | Pharmaceutical composition of donepezil | |
US20110165235A1 (en) | Directly pressed aliskiren tablets | |
CN102526063A (en) | Compound preparation containing losartan potassium and hydrochlorothiazide and preparation method for compound preparation | |
US20130337063A1 (en) | Pharmaceutical compositions of maraviroc and process for the preparation thereof | |
CN107157945B (en) | Novel opium delta receptor stimulant hydrochloride tablet and preparation method thereof | |
WO2023080854A1 (en) | Lurasidone hydrochloride compositions | |
US20220175774A1 (en) | Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor | |
US20220117961A1 (en) | Pharmaceutical composition comprising phthalazinone derivatives | |
EP2976067A1 (en) | Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof | |
WO2012172413A1 (en) | Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof | |
WO2019154218A1 (en) | Composition of aminopyran derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: CORERX, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCMILLAN, BRIAN;GREENE, MATTHEW;SIGNING DATES FROM 20160610 TO 20160713;REEL/FRAME:061770/0080 Owner name: OTSUKA AMERICA PHARMACEUTICAL, INC., MARYLAND Free format text: MERGER;ASSIGNOR:NEUROVANCE, INC.;REEL/FRAME:061770/0117 Effective date: 20171130 Owner name: NEUROVANCE, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CORERX, INC.;REEL/FRAME:061531/0792 Effective date: 20160714 Owner name: NEUROVANCE, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCKINNEY, ANTHONY;PISKORSKI, WALTER;SIGNING DATES FROM 20160608 TO 20160609;REEL/FRAME:061531/0769 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |